INmune Bio, Inc.
INMB
$7.32
$0.010.14%
NASDAQ
12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
---|---|---|---|---|---|
Net Income | -9.22M | -12.09M | -9.75M | -11.03M | -8.41M |
Total Depreciation and Amortization | -- | -- | -- | -- | -- |
Total Amortization of Deferred Charges | 6.00K | 15.00K | 24.00K | 34.00K | 45.00K |
Total Other Non-Cash Items | 1.76M | 1.72M | 2.35M | 1.78M | 1.88M |
Change in Net Operating Assets | -3.56M | 3.37M | -514.00K | 1.74M | 3.08M |
Cash from Operations | -11.01M | -6.99M | -7.89M | -7.48M | -3.40M |
Capital Expenditure | -- | -- | -- | -- | -- |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | -- | -- | -- | -- | -- |
Cash from Investing | -- | -- | -- | -- | -- |
Total Debt Issued | -- | -- | -- | -- | -- |
Total Debt Repaid | -2.50M | -2.50M | -2.50M | -2.50M | -2.50M |
Issuance of Common Stock | 422.00K | 12.29M | 15.50M | -- | 0.00 |
Repurchase of Common Stock | -- | -- | -- | -- | -- |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -- | -- | -- | -- | -- |
Cash from Financing | -2.08M | 9.79M | 13.00M | -2.50M | -2.50M |
Foreign Exchange rate Adjustments | 461.00K | -323.00K | -44.00K | 130.00K | -64.00K |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | -12.63M | 2.48M | 5.07M | -9.85M | -5.97M |